DL-Asn-NHi-Pr | 86409-04-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: DL-Asn-NHi-Pr
• 英文别名: N~1~-isopropylaspartamide hydrochloride；2-amino-N-propan-2-ylbutanediamide
• CAS: 86409-04-3
• 化学式: C₇H₁₅N₃O₂
• 分子量: 173.215
• InChiKey: RIIIQWXLBGQIRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  98.2
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  DL-Asn-NHi-Pr 以 二氯甲烷 为溶剂， 反应 0.46h， 生成 Piv-L-Asn-NHi-Pr
  参考文献：
  名称：

  Hosten, N.; Anteunis, M. J. O., Bulletin des Societes Chimiques Belges, 1988, vol. 97, # 1, p. 45 - 47

  摘要：

  DOI：
• 作为产物：
  描述：

  异丙胺 、 2,5-二氧代恶唑烷-4-乙酰胺 以 二氯甲烷 为溶剂， 生成 DL-Asn-NHi-Pr
  参考文献：
  名称：

  Hosten, N.; Anteunis, M. J. O., Bulletin des Societes Chimiques Belges, 1988, vol. 97, # 1, p. 45 - 47

  摘要：

  DOI：

文献信息

• Lincomycin Derivatives and Antimicrobial Agents Comprising the Same as Active Ingredient
  申请人：Umemura Eijirou

  公开号：US20090156512A1

  公开（公告）日：2009-06-18

  This invention provides compounds of formula (I) or its pharmacologically acceptable salt or solvate, wherein A represents aryl or a monocyclic or bicyclic heterocyclic group, R 1 represents a halide, nitro, substituted C 1-6 alkyl, optionally substituted amino, C 1-6 alkyloxycarbonyl, optionally substituted aryl, a heterocyclic group, or heterocyclic carbonyl, R 2 represents a hydrogen atom or C 1-6 alkyl, R 3 represents C 1-6 alkyl, all of R 4 , R 5 , and R 6 represent a hydrogen atom, R 7 represents C 1-6 alkyl, m is 1 or 2, and n is 1. The compounds are novel lincomycin derivatives having a potent activity against resistant pneumococci. The compounds can be used as an antimicrobial agent and are useful for preventing or treating bacterial infectious diseases.

  本发明提供了式（I）的化合物或其药理学上可接受的盐或溶剂，其中A代表芳基或单环或双环杂环基，R1代表卤素、硝基、取代的C1-6烷基、可选取代的氨基、C1-6烷氧羰基、可选取代的芳基、杂环基或杂环羰基，R2代表氢原子或C1-6烷基，R3代表C1-6烷基，R4、R5和R6均代表氢原子，R7代表C1-6烷基，m为1或2，n为1。这些化合物是新型的林可霉素衍生物，对耐药性肺炎球菌具有强大的活性。这些化合物可以用作抗微生物剂，并且对于预防或治疗细菌感染性疾病是有用的。
• Polyene macrolide derivative
  申请人：Shionogi & Co., Ltd.

  公开号：US10696707B2

  公开（公告）日：2020-06-30

  The present invention is the following Amphotericin B derivative: wherein each symbol is defined in description. The compound of the present invention has 16th position (X) is urea structure, cyclic structure, hydroxyalkyl or substituted monoalkylcarbamoyl. The compound of the present invention has antifungal activity.

  本发明是以下两性霉素 B 衍生物： 其中各符号在说明中定义。本发明化合物的第 16 位（X）是脲结构、环状结构、羟烷基或取代的单烷基氨基甲酰基。本发明化合物具有抗真菌活性。
• Salts of sulfodehydroabietic acid and treatment of gastro-intestinal diseases
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：EP0078152B1

  公开（公告）日：1986-05-07
• POLYENE MACROLIDE DERIVATIVE
  申请人：Shionogi & Co., Ltd.

  公开号：US20170190729A1

  公开（公告）日：2017-07-06

  The present invention is the following Amphotericin B derivative: wherein each symbol is defined in description. The compound of the present invention has 16th position (X) is urea structure, cyclic structure, hydroxyalkyl or substituted monoalkylcarbamoyl. The compound of the present invention has antifungal activity.
• TLR7/8 ANTAGONISTS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20200316051A1

  公开（公告）日：2020-10-08

  A treatment of disorders related to TLR7/8 overexpression or aberrant activation is provided. The disorder may include multiple sclerosis, Alzheimer's Disease, myositis, stroke, ischemia, CNS neuropathies, systemic lupus erythematosus, lupus nephritis, Sjogren's syndrome, Guillain-Barré syndrome, alcoholic hepatitis, non-alcoholic steatohepatitis, congenital heart block, autoimmune hepatitis, autoimmune pancreatitis, adult onset Still's disease, drug-induced neurological disorders, and substance addiction. A compound of Formula (I) is useful to treat such disorders.